JP2014532726A5 - - Google Patents

Download PDF

Info

Publication number
JP2014532726A5
JP2014532726A5 JP2014540154A JP2014540154A JP2014532726A5 JP 2014532726 A5 JP2014532726 A5 JP 2014532726A5 JP 2014540154 A JP2014540154 A JP 2014540154A JP 2014540154 A JP2014540154 A JP 2014540154A JP 2014532726 A5 JP2014532726 A5 JP 2014532726A5
Authority
JP
Japan
Prior art keywords
thio
pyridin
cyanonaphthalen
acceptable salt
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014540154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014532726A (ja
JP6025853B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/063415 external-priority patent/WO2013067425A1/en
Publication of JP2014532726A publication Critical patent/JP2014532726A/ja
Publication of JP2014532726A5 publication Critical patent/JP2014532726A5/ja
Application granted granted Critical
Publication of JP6025853B2 publication Critical patent/JP6025853B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014540154A 2011-11-03 2012-11-02 3,4−二置換ピリジン化合物、その使用方法、および、該化合物を含む組成物 Expired - Fee Related JP6025853B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161555450P 2011-11-03 2011-11-03
US61/555,450 2011-11-03
US201261616363P 2012-03-27 2012-03-27
US61/616,363 2012-03-27
PCT/US2012/063415 WO2013067425A1 (en) 2011-11-03 2012-11-02 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same

Publications (3)

Publication Number Publication Date
JP2014532726A JP2014532726A (ja) 2014-12-08
JP2014532726A5 true JP2014532726A5 (https=) 2015-12-24
JP6025853B2 JP6025853B2 (ja) 2016-11-16

Family

ID=47178362

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014540154A Expired - Fee Related JP6025853B2 (ja) 2011-11-03 2012-11-02 3,4−二置換ピリジン化合物、その使用方法、および、該化合物を含む組成物

Country Status (21)

Country Link
US (2) US10047050B2 (https=)
EP (2) EP3501520A1 (https=)
JP (1) JP6025853B2 (https=)
KR (1) KR101988066B1 (https=)
CN (2) CN106963761A (https=)
AU (1) AU2012332154B2 (https=)
BR (1) BR112014010495A2 (https=)
CA (1) CA2852490A1 (https=)
DK (1) DK2776028T3 (https=)
EA (1) EA026101B1 (https=)
ES (1) ES2704233T3 (https=)
HU (1) HUE040625T2 (https=)
IL (1) IL232105A (https=)
MX (1) MX352904B (https=)
MY (1) MY180138A (https=)
PH (1) PH12014500997A1 (https=)
PL (1) PL2776028T3 (https=)
SG (1) SG11201402016PA (https=)
UA (1) UA114304C2 (https=)
WO (1) WO2013067425A1 (https=)
ZA (1) ZA201402795B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081930A1 (es) * 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
EP3501520A1 (en) 2011-11-03 2019-06-26 Ardea Biosciences, Inc. 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same
CN105439946B (zh) * 2014-08-13 2018-02-02 益方生物科技(上海)有限公司 羧酸化合物及其制备方法和用途
CN104292124B (zh) * 2014-09-27 2016-01-20 张远强 硝基苯基取代的萘环丁二酸酰胺衍生物、其制备方法及用途
CN104311452B (zh) * 2014-09-27 2016-01-06 张远强 腈基萘环的丁二酸酰胺衍生物、其制备方法及用途
CN108026043A (zh) * 2015-08-14 2018-05-11 广东东阳光药业有限公司 一种萘环化合物的晶型
PE20181521A1 (es) * 2015-12-08 2018-09-24 Ardea Biosciences Inc Composicion farmaceutica que comprende un potente inhibidor de urat1
CN105884807A (zh) * 2016-04-26 2016-08-24 昆药集团股份有限公司 硼酸频那醇酯衍生物的制备方法、硫代乙酸盐化合物的制备方法
CN106117130A (zh) * 2016-06-28 2016-11-16 昆药集团股份有限公司 一种2‑((3‑(4‑氰基萘‑1‑基)吡啶‑4‑基)硫基)‑2‑甲基丙酸的晶型及其制备方法和药物组合物
CN114315715B (zh) * 2020-09-29 2024-02-20 杭州中美华东制药有限公司 一类urat1抑制剂及其制备方法与应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6054310B2 (ja) 1979-02-21 1985-11-29 三井東圧化学株式会社 ピリダジン誘導体と農園芸用殺菌剤
US4889868A (en) 1984-12-20 1989-12-26 Rorer Pharmaceutical Corporation Bis-imidazolinoamino derivatives as antiallergy compounds
US5051442A (en) 1990-04-25 1991-09-24 Merrell Dow Pharmaceuticals Inc. 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof
ES2092580T3 (es) 1990-11-30 1996-12-01 Teijin Ltd Derivado de 2-ariltiazol y composicion farmaceutica que contiene el mismo.
US5405873A (en) 1992-09-10 1995-04-11 Banyu Pharmaceutical Co., Ltd. Substituted acetamide derivatives
US5344651A (en) 1993-07-23 1994-09-06 The Procter & Gamble Company Cyproterone acetate thioacetate
WO1995029897A1 (en) 1994-04-29 1995-11-09 G.D. Searle & Co. METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS
US6017925A (en) 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
WO2001091796A2 (en) * 2000-06-01 2001-12-06 Guilford Pharmaceuticals Inc. Methods, compounds and compositions for treating gout
GB0108339D0 (en) 2001-04-03 2001-05-23 Syngenta Participations Ag Organics compounds
JP3824899B2 (ja) * 2001-09-21 2006-09-20 株式会社ヒューマンセルシステムズ 腎臓及び胎盤型尿酸トランスポーターとその遺伝子
DK2135608T3 (da) 2004-08-25 2012-01-23 Ardea Biosciences Inc S-triazolyl-alfa-mercaptoacetanilider som inhibitorer for HIV-revers transkriptase
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
US20070099970A1 (en) 2005-08-19 2007-05-03 Mackerell Alexander Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain
AU2007230991A1 (en) 2006-03-22 2007-10-04 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with ER stress
CA2662242C (en) 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
ME01294B (me) 2007-11-27 2013-06-20 Ardea Biosciences Inc Nova jedinjenja i kompozicije i metode upotrebe
NZ588374A (en) * 2008-04-30 2012-11-30 Wellstat Therapeutics Corp Tetrazole compounds for reducing uric acid
CA2736117C (en) 2008-09-04 2013-11-19 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
EP2432468A2 (en) 2009-05-20 2012-03-28 Ardea Biosciences, Inc. Methods of modulating uric acid levels
EP2432774A4 (en) 2009-05-20 2013-01-02 Ardea Biosciences Inc COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID RATES
WO2011044140A1 (en) 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Substituted thioacetic acid salicylate derivatives and their uses
MX2012007925A (es) 2010-01-08 2012-08-03 Ardea Biosciences Inc Formas polimorficas, cristalinas y de mesofase de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-ilti o)acetato de sodio, y usos de las mismas.
EP2560642A4 (en) * 2010-03-30 2013-12-18 Ardea Biosciences Inc TREATMENT OF GICHT
EP2582683B1 (en) * 2010-06-15 2018-03-21 Ardea Biosciences, Inc. Treatment of gout and hyperuricemia
BR112012032193A2 (pt) 2010-06-16 2019-09-24 Ardea Biosciences Inc composto, composiçoes e métodos de uso de feniltioacetato
AR081930A1 (es) * 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
EP3501520A1 (en) * 2011-11-03 2019-06-26 Ardea Biosciences, Inc. 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same
PE20181521A1 (es) * 2015-12-08 2018-09-24 Ardea Biosciences Inc Composicion farmaceutica que comprende un potente inhibidor de urat1

Similar Documents

Publication Publication Date Title
JP2014532726A5 (https=)
JP2013528655A5 (https=)
JP6097888B2 (ja) 新規使用
JP2014532647A5 (https=)
JP2013528650A5 (https=)
JP5978216B2 (ja) テオフィリンとフェブキソスタットの併用療法のための方法
JP2012184234A5 (https=)
JP2014532760A5 (https=)
JP2013521304A5 (https=)
TW201249432A (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
DK3027183T3 (en) SELECTIVE AT2 RECEPTOR AGONISTS FOR USING CACKSY TREATMENT
JP2013087119A5 (https=)
RU2014115733A (ru) Новая соль и медицинское применение
JP2014532758A5 (https=)
JP2014532759A5 (https=)
JP2013518061A5 (https=)
PE20240764A1 (es) Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico
JP2009532498A (ja) 有機化合物の組合せ
JP2013507383A5 (https=)
EP2568982B1 (en) Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
EP4344701A1 (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
JP2021519313A5 (https=)
JP2022541482A (ja) ベリヌラドを含む用量ダンピング耐性医薬組成物
JP2016505628A5 (https=)
US20240415814A1 (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid